Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$20.42 -2.4%	$19.22	$14.40 ▼ $47.00	$1.36B	1.33	917,863 shs	904,286 shs
DVAX Dynavax Technologies	$10.18 -2.4%	$10.51	$9.22 ▼ $14.63	$1.22B	1.07	2.19 million shs	1.30 million shs
INVA Innoviva	$21.37 -0.7%	$18.82	$15.69 ▼ $21.98	$1.34B	0.37	666,080 shs	711,135 shs
PGNX Progenics Pharmaceuticals	$4.10	$4.10	$1.89 ▼ $6.37	$355.05M	1.89	1.16 million shs	34.93 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-2.39%	+3.81%	+1.19%	+1.39%	-42.59%
DVAX Dynavax Technologies	-2.40%	+2.93%	+3.35%	-25.64%	-15.80%
INVA Innoviva	-0.74%	+2.35%	+14.83%	+22.89%	+34.40%
PGNX Progenics Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.9182 of 5 stars	4.5	3.0	0.0	0.0	3.4	0.0	0.0
DVAX Dynavax Technologies	4.1705 of 5 stars	3.3	1.0	0.0	4.7	2.0	1.7	1.9
INVA Innoviva	4.1473 of 5 stars	3.5	0.0	0.0	4.2	2.6	1.7	1.9
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$53.90	163.96% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	135.76% Upside
INVA Innoviva	3.00	Buy	$55.00	157.37% Upside
PGNX Progenics Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PGNX, CLDX, INVA, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/17/2025	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$12.00 ➝ $10.00
3/20/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$46.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.56M	179.33	N/A	N/A	$9.08 per share	2.25
DVAX Dynavax Technologies	$294.62M	4.15	N/A	N/A	$4.81 per share	2.12
INVA Innoviva	$369.84M	3.63	$4.13 per share	5.17	$10.66 per share	2.00
PGNX Progenics Pharmaceuticals	$34.99M	10.15	N/A	N/A	$0.54 per share	7.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	8/6/2025 (Estimated)
DVAX Dynavax Technologies	-$6.39M	-$0.52	56.56	20.78	N/A	9.85%	4.22%	2.67%	8/5/2025 (Estimated)
INVA Innoviva	$179.72M	-$1.01	30.97	13.79	N/A	18.31%	20.84%	11.38%	7/29/2025 (Estimated)
PGNX Progenics Pharmaceuticals	-$68.55M	-$0.80	N/A	N/A	N/A	-180.28%	-129.46%	-53.23%	N/A

Latest PGNX, CLDX, INVA, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
DVAX Dynavax Technologies	0.33	13.23	12.34
INVA Innoviva	0.38	1.79	1.64
PGNX Progenics Pharmaceuticals	0.99	2.12	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
INVA Innoviva	99.12%
PGNX Progenics Pharmaceuticals	70.96%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
DVAX Dynavax Technologies	2.98%
INVA Innoviva	2.25%
PGNX Progenics Pharmaceuticals	4.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	127.54 million	Optionable
INVA Innoviva	100	62.78 million	61.54 million	Optionable
PGNX Progenics Pharmaceuticals	79	86.60 million	N/A	Optionable

PGNX, CLDX, INVA, and DVAX Headlines

Recent News About These Companies

Antibody–drug conjugates for cancer: poised to deliver?

October 28, 2024 | nature.com

BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals

August 19, 2024 | br.advfn.com

PGNX_old Historical Data

October 28, 2023 | investing.com

Investing in Pharmaceutical Stocks

March 3, 2023 | fool.com

Deciphera Pharmaceuticals Stock (NASDAQ:DCPH), Quotes and News Summary

February 24, 2023 | benzinga.com

Opioid Induced Constipation (OIC) Drug Market Size in 2023 | NEWEST REPORT | Touch New Level in Forthcoming year till 2028

February 13, 2023 | marketwatch.com

Insights on the Flexible Manufacturing Systems for Pharmaceutical Industry Global Market to 2031 - by Product Type, Technology, End-user and Region

February 11, 2023 | finance.yahoo.com

I've Got an Options Bandage for a Sick Economy

June 19, 2022 | realmoney.thestreet.com

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

January 21, 2022 | thestreet.com

What Falling Estimates & Price Mean for Progenics (PGNX)

October 27, 2021 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNX, CLDX, INVA, and DVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$20.42 -0.50 (-2.39%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$20.42 0.00 (0.00%)

As of 03:59 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$10.18 -0.25 (-2.40%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$10.18 0.00 (0.00%)

As of 03:59 AM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Innoviva NASDAQ:INVA

$21.37 -0.16 (-0.74%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$21.37 0.00 (0.00%)

As of 03:59 AM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time